UroGen Pharma (URGN) Inventory (2016 - 2026)
UroGen Pharma's (URGN) quarterly Inventory came in at $20.9 million in Q1 2026, up 175.64% YoY from $7.6 million in Q1 2025, and up 27.07% on a QoQ basis from $16.5 million in Q4 2025.
Analysis
UroGen Pharma (URGN) Inventory (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Inventory data on file, last reported at $20.9 million in Q1 2026.
- Quarterly Inventory rose 175.64% year-over-year to $20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 million (up 175.64% YoY) and the FY2025 annual result came in at $16.5 million, up 78.43% from the prior year.
- Inventory advanced to $20.9 million in Q1 2026, from $16.5 million in the prior quarter.
- In the past five years, Inventory ranged from a high of $20.9 million in Q1 2026 to a low of $4.3 million in Q4 2022.
- A 5-year average of $7.8 million and a median of $7.1 million in 2025 frame the typical range for Inventory.
- Annual changes were most pronounced in 2022 — Inventory declined 10.49% — and 2026, when it soared 175.64%.
- Tracing URGN's Inventory over 5 years: stood at $4.3 million in 2022, then soared by 31.17% to $5.7 million in 2023, then soared by 62.65% to $9.2 million in 2024, then jumped by 78.43% to $16.5 million in 2025, then gained by 27.07% to $20.9 million in 2026.
- The last three Inventory figures came in at $20.9 million (Q1 2026), $16.5 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 3.08 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 371.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 280.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 732.60 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 97.11 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 142.38 Mn |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn | 24.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.59 Mn |
| Mar 31, 2026 | 20.92 Mn |
| Dec 31, 2025 | 16.46 Mn |
| Sep 30, 2025 | 8.34 Mn |
| Jun 30, 2025 | 7.13 Mn |
| Mar 31, 2025 | 7.59 Mn |
| Dec 31, 2024 | 9.23 Mn |
| Sep 30, 2024 | 7.59 Mn |
| Jun 30, 2024 | 7.44 Mn |
| Mar 31, 2024 | 7.24 Mn |
| Dec 31, 2023 | 5.67 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Jun 30, 2023 | 4.99 Mn |
| Mar 31, 2023 | 5.47 Mn |
| Dec 31, 2022 | 4.33 Mn |
| Sep 30, 2022 | 4.86 Mn |
| Jun 30, 2022 | 5.05 Mn |
| Mar 31, 2022 | 4.76 Mn |
| Dec 31, 2021 | 4.83 Mn |
| Sep 30, 2021 | 3.81 Mn |